Source: Annual Congress 2009 - Methodological aspects of asthma and COPD epidemiology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Ruffin, S. Appleton, R. Brito-Mutunayagam, D. Wilson, R. Adams (Adelaide, Rockhampton, Australia). Excess lung function decline is associated with GOLD stage 0. Eur Respir J 2009; 34: Suppl. 53, 1002

Member's Comments

No comment yet.

Related content which might interest you: GOLD stage 0 and risk of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 352s Year: 2003 Total mortality risks in relation to the GOLD stages in a long term follow-up - a special analysis of GOLD stage 0 Source: Annual Congress 2004 - Burden of obstructive lung diseases: costs, mortality and life impairment Year: 2004 Relation of various parameters to the survival rate in stage 0 to stage IIa chronic obstructive pulmonary disease (COPD) according to the GOLD guidelines Source: Eur Respir J 2003; 22: Suppl. 45, 578s Year: 2003 The effect of changing GOLD severity stage on long-term mortality in COPD Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Lung function decline and variability in end stage cystic fibrosis Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 The prevalence of QTc-prolongation increase by GOLD stage in COPD Source: International Congress 2017 – Prevalence, prognosis and comorbidities of COPD and factors associated with lung function Year: 2017 Yearly progression of low lung attenuation area in low dose CT scan for aymptomatic current smokers with normal lung function or GOLD stage I COPD Source: Annual Congress 2013 –Lung function tests to monitor airway diseases Year: 2013 Calculation of Scond between 0 and 3 lung turn over (Scond*) in mild to moderate chronic lung disease Source: International Congress 2016 – What's new in paediatric respiratory physiology? Year: 2016 Stage 0 in GOLD does not predict future clinical COPD Source: Eur Respir J 2002; 20: Suppl. 38, 401s Year: 2002 COPD GOLD stage 1: Is it really a disease? Source: Annual Congress 2011 - COPD mechanisms Year: 2011 Prevalence of small airway dysfunction among GOLD stages in COPD patients Source: International Congress 2016 – Functional assessment of the airways Year: 2016 Effects of tiotropium on lung volumes during exercise in GOLD stage II to IV COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 171s Year: 2006 Increased circulating fibrocytes associated with lung function decline in COPD patients with desaturation during 6 minute walk test Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Pre-treatment lung function decline stabilizes up to 3 year after targeted lung denervation in COPD Source: Virtual Congress 2020 – The hot and cold of interventional pulmonology Year: 2020 Effect of posture on lung clearance index (LCI) and lung volumes in children with early stage cystic fibrosis lung disease Source: International Congress 2015 – Lung function: effects on method, machine and disease on the measurement Year: 2015 Prediction of respiratory disease mortality in a population sample is improved by expressing lung function impairment as FEV1 quotient Source: Eur Respir J 2005; 26: Suppl. 49, 217s Year: 2005 Use of quality of life measures and FEF25-75 to stratify GOLD stage I COPD into stage IA and stage IB Source: Eur Respir J 2002; 20: Suppl. 38, 122s Year: 2002 Predicting an accelerated lung function decline in smokers: is there a proper threshold? Source: Eur Respir J 2014; 43: 307-308 Year: 2004 Predicting an accelerated lung function decline in smokers: is there a proper threshold? Source: Eur Respir J 2014; 43: 308-309 Year: 2004 Responses to polymeric lung volume reduction (PLVR) therapy at 6 months in patients with GOLD stage III emphysema Source: Annual Congress 2010 - Interventions for obstructive lung diseases Year: 2010